Company intelligence / Profile preview

Proteomics International Laboratories

Perth, Western Australia, Australiaproteomics.com.au ↗

Ownership: Private
Development stage: Other

Overview

Proteomics International Laboratories has commercialized its lead diagnostic product, PromarkerD—a predictive blood test for diabetic kidney disease—now launched in Australia and the US. Its pipeline includes late-stage clinical validation of non-invasive blood tests such as PromarkerEndo (for endometriosis) and PromarkerEso (for esophageal cancer), both showing strong accuracy in recent studies. The company also offers accredited analytical services to pharma/biotech clients globally.

Therapeutic areas: NephrologyOncologyWomen's HealthOther
Modalities: Diagnostic test (platform-based)Protein biomarker assayMass spectrometry-based diagnostics and analyticsBiosimilar/biologic analytical services
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Proteomics International Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteomics International Laboratories.

Explore the full profile